Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
| Status: | Archived |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | December 2010 |
A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.The primary
objective of this study is to evaluate the efficacy, as measured by overall response rate,
of orally administered PLX3397 in patients with relapsed or refractory classical Hodgkin
lymphoma (HL). Secondary objectives include safety, the duration of response, the disease
control rate, progression free survival, and how the drug affects your body.
We found this trial at
5
sites
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
Click here to add this to my saved trials
Northwestern University Northwestern is recognized both nationally and internationally for the quality of its educational...
Click here to add this to my saved trials
136 Mountainview Blvd
Basking Ridge, New Jersey 7920
Basking Ridge, New Jersey 7920
(908) 542-3000
Memorial Sloan-Kettering Cancer Center - Basking Ridge At Memorial Sloan Kettering Basking Ridge, we offer...
Click here to add this to my saved trials
10833 Le Conte Ave
Los Angeles, California 90095
Los Angeles, California 90095
(310) 825-4321
David Geffen School of Medicine, UCLA In 2002 Mr. David Geffen announced a $200 million...
Click here to add this to my saved trials
Click here to add this to my saved trials